1. Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis.
- Author
-
Mikhaylenko, Dmitry S., Kuznetsova, Ekaterina B., Musatova, Viktoria V., Bure, Irina V., Deryagina, Tatiana A., Alekseeva, Ekaterina A., Tarasov, Vadim V., Zamyatnin Jr., Andrey A., and Nemtsova, Marina V.
- Subjects
- *
RHEUMATOID arthritis , *RHEUMATOID factor , *SINGLE nucleotide polymorphisms , *ALLELES , *THERAPEUTICS , *RECEIVER operating characteristic curves , *MONOCLONAL antibodies - Abstract
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease and its treatment is an urgent problem of rheumatology. Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 and is one of the few promising drugs for RA therapy. One-hundred-and-twenty-five DNA samples from Russian patients with RA, treated with olokizumab, were genotyped with an NGS panel containing 60 single nucleotide polymorphisms (SNPs) and the whole coding sequences of IL6, IL6R, TNFRSF1A, CTLA4, IL10, IL23R, and PADI4; and by RT-PCR for HLA-DRB1 and HLA-B. Associations of polymorphic variants with olokizumab efficacy according to the scores ACR20, ACR50, and DAS28-CRP were determined. We analyzed the obtained data by using logistic regression, ROC curves, and multivariate ANOVA. A high predictive value of the response to olokizumab therapy at 24 weeks was found for the combination of HLA-DRB1*04 and HLA-B*27 alleles with SNPs located in non-HLA genes (IL1B, IL17A, PADI4, DHODH, GLCCI1, IL23R, and TNFAIP3), and clinical characteristics (age, RA duration, and intensity) according to ACR20. Thus, the comprehensive assessment of polymorphic variants of HLA and non-HLA genes considering population characteristics in combination with clinical parameters allows for the elaboration of an RA prognostic panel. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF